Zheng Z M, Quintero J, Reid E S, Gocke C, Baker C C
Basic Research Laboratory, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Virol. 2000 Jul;74(13):5902-10. doi: 10.1128/jvi.74.13.5902-5910.2000.
Alternative splicing is a critical component of the early to late switch in papillomavirus gene expression. In bovine papillomavirus type 1 (BPV-1), a switch in 3' splice site utilization from an early 3' splice site at nucleotide (nt) 3225 to a late-specific 3' splice site at nt 3605 is essential for expression of the major capsid (L1) mRNA. Three viral splicing elements have recently been identified between the two alternative 3' splice sites and have been shown to play an important role in this regulation. A bipartite element lies approximately 30 nt downstream of the nt 3225 3' splice site and consists of an exonic splicing enhancer (ESE), SE1, followed immediately by a pyrimidine-rich exonic splicing suppressor (ESS). A second ESE (SE2) is located approximately 125 nt downstream of the ESS. We have previously demonstrated that the ESS inhibits use of the suboptimal nt 3225 3' splice site in vitro through binding of cellular splicing factors. However, these in vitro studies did not address the role of the ESS in the regulation of alternative splicing. In the present study, we have analyzed the role of the ESS in the alternative splicing of a BPV-1 late pre-mRNA in vivo. Mutation or deletion of just the ESS did not significantly change the normal splicing pattern where the nt 3225 3' splice site is already used predominantly. However, a pre-mRNA containing mutations in SE2 is spliced predominantly using the nt 3605 3' splice site. In this context, mutation of the ESS restored preferential use of the nt 3225 3' splice site, indicating that the ESS also functions as a splicing suppressor in vivo. Moreover, optimization of the suboptimal nt 3225 3' splice site counteracted the in vivo function of the ESS and led to preferential selection of the nt 3225 3' splice site even in pre-mRNAs with SE2 mutations. In vitro splicing assays also showed that the ESS is unable to suppress splicing of a pre-mRNA with an optimized nt 3225 3' splice site. These data confirm that the function of the ESS requires a suboptimal upstream 3' splice site. A surprising finding of our study is the observation that SE1 can stimulate both the first and the second steps of splicing.
可变剪接是乳头瘤病毒基因表达从早期到晚期转换的关键组成部分。在1型牛乳头瘤病毒(BPV-1)中,3'剪接位点的使用从核苷酸(nt)3225处的早期3'剪接位点转换为nt 3605处的晚期特异性3'剪接位点,这对于主要衣壳(L1)mRNA的表达至关重要。最近在两个可变3'剪接位点之间鉴定出三个病毒剪接元件,并已证明它们在这种调节中起重要作用。一个二分元件位于nt 3225 3'剪接位点下游约30 nt处,由一个外显子剪接增强子(ESE)SE1组成,紧接着是一个富含嘧啶的外显子剪接抑制子(ESS)。第二个ESE(SE2)位于ESS下游约125 nt处。我们之前已经证明,ESS通过结合细胞剪接因子在体外抑制次优的nt 3225 3'剪接位点的使用。然而,这些体外研究没有涉及ESS在可变剪接调节中的作用。在本研究中,我们分析了ESS在体内BPV-1晚期前体mRNA可变剪接中的作用。仅ESS的突变或缺失并没有显著改变正常的剪接模式,在这种模式中nt 3225 3'剪接位点已经被主要使用。然而,一个在SE2中含有突变的前体mRNA主要使用nt 3605 3'剪接位点进行剪接。在这种情况下,ESS的突变恢复了nt 3225 3'剪接位点的优先使用,表明ESS在体内也作为剪接抑制子发挥作用。此外,次优的nt 3225 3'剪接位点的优化抵消了ESS的体内功能,并导致即使在具有SE2突变的前体mRNA中也优先选择nt 3225 3'剪接位点。体外剪接试验还表明,ESS无法抑制具有优化的nt 3225 3'剪接位点的前体mRNA的剪接。这些数据证实,ESS的功能需要一个次优的上游3'剪接位点。我们研究中一个令人惊讶的发现是观察到SE1可以刺激剪接的第一步和第二步。